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Cardiovascular disease (CVD) has been, and still is, the number one cause of death across the 
world, with 1 of each 3 person dying due to CVD. One of the known causes of CVD is atherogenic 
dyslipidemia. Dyslipidemia can be treated pharmacologically with HMG-CoA reductase inhibitors 
(statins) and/or with dietary changes. Clinical guidelines emphasize the use of statins for people 
at risk, yet accompanied dietary interventions have also shown promising results. Omega-3 fatty 
acids (OM-3 FA), especially animal derived EPA and DHA are recognised as anti-atherogenic 
nutrients with several proven beneficial impacts on cardiovascular outcomes such as reduced CV 
mortality or reduced CV events such as stroke and MI. Studies that investigate the role of EPA 
and DHA in lipid management therapy point to significant reductions in blood TAG, non-HDL-C 
and VLDL-C. LDL-C might slightly increase with high-dose n-3 supplementation but this effect is 
neutralised when combined with statins. When added to statin therapy, there are further 
benefits of EPA and DHA in altering blood lipids including a shift from small&dense LDL-C particles 
to less atherogenic large&buoyant ones. More research is needed in the role of combination 
therapies in lipid management including LDL-C particle size and concentration. 
Introduction  
Cardiovascular disease is the major cause of deaths and loss of disability-adjusted life years 
in the world (World Health Organization, 2016). Prevention of CVD can be achieved with a cardio-
protective lifestyle including a healthy diet. Nonetheless, for established CV risks such as 
dyslipidemia, more advanced clinical strategies are required. Management of blood lipids usually 
involve pharmacological agents as defined by clinical guidelines. Most clinical guidelines consider 
blood lipids as traditional risk factors and focus on low density lipoprotein cholesterol (LDL-C) 





CoA reductase inhibitors (statins) are suggested by all clinical guidelines as the gold standard in 
management of atherogenic dyslipidemia in order to reduce elevated LDL-C and non-HDL-C 
levels.  Even though not yet present as a treatment target in the clinical guidelines, a more 
recently discovered risk factor, small & dense LDL-C particles, are suggested by several studies as 
the most atherogenic lipoprotein particle (Hoogeveen et al., 2014). 
Even though statins are the main therapeutic agent in treatment of dyslipidemia, evidence states 
that there is a considerable role of diet in development and management of lipid-related 
problems (Thompkinson, Bhavana & Kanika, 2014). Certain nutrients are known as atherogenic, 
meaning that they aggravate the atherogenic process, while certain nutrients are anti-
atherogenic. The polyunsaturated OM-3 FA are among the most-investigated anti-atherogenic 
nutrients (Mozaffarian & Wu, 2011). Studies that analysed the relation between OM-3 intake and 
CV end points point to a negative correlation (Burr et al., 1989; GISSI, 1999; Stark, Park & Maines, 
2000). A subset of these studies analyse the physiologic effects of OM-3 on CV blood markers 
including blood lipids such as TAG, HDL-C, LDL-C and non-HDL-C.  Their results collectively 
highlight the beneficial effects of OM-3 on these parameters either when used alone or in 
combination with statins. Albeit limited, there are also studies that investigate the alterations in 
LDL-C particle size and concentration with OM-3 use (Contacos, Barter & Sullivan, 1993; Nordøy, 
Hansen, Brox & Svensson, 2001; Maki et al., 2008). This review aims at understanding blood lipids 
as separate CV risk factors and analyse the literature that studied the correlation between OM-3 







Cardiovascular Disease  
Definition and Prevalence  
CVD is defined by the World Health Organisation (2014) as a family of conditions that have 
an impact on heart and blood vessels. According to the Joint British Societies (2014) most of the 
CVD are caused by a common pathology of “atherosclerosis”, which is the condition when a 
person’s arteries are blocked by fatty plaques. Atherosclerosis causes CVD within time, when the 
blood supply to an organ or tissues is completely blocked by narrowed arteries or ruptured 
plaques, resulting in limited amounts of blood and oxygen flow to that area (British Heart 
Foundation, 2013). Heart attacks and strokes are usually acute events that are mainly caused by 
such blockage, in turn. 
In 1996, Murray and Lopez stated that cardiovascular disease is the major cause of 
mortality and loss of disability-adjusted life years in the world. Since then, 20 years have passed 
yet CVD still ranks first in the world in terms of death cause, which can be interpreted as that the 
number of people that die from CVD every year exceed that of other diseases. According to World 
Health Organization (2016), 17.5 million people died from CVD in 2012, which consisted 31% of 
the overall deaths globally and more than three quarters of them took place in low- and middle-
income countries. The annual costs of the disease are estimated at approximately 863 billion USD 
and the burden is expected to increase as a consequence of the rapid increase in obesity and the 
ageing populations (Julius, 2017). 
Lipids as Traditional CVD Risk Factors  
Atherosclerosis is a degenerative disease of the inner wall of the vascular endothelium. 





wall, hence, change in their phenotype causes dysfunction of the vessel wall, which, in turn, leads 
to atherosclerosis (Douglas & Channon, 2010). One of the etiological causes of atherosclerosis is 
considered to be dyslipidaemia, a cluster of lipid abnormalities (Grooper & Smith, 2013), ever 
since the Framingham Study defined lipids as CVD risk factors in early 1950s (Kannel, Dawber, 
Friedman, Glennon & McNamara, 1964) and Keys formulated the cholesterol hypothesis in 1951. 
Elevated Triacylglycerol (TAG) levels and low-density lipoprotein cholesterol (LDL-C), usually 
accompanied with low levels of high-density lipoprotein cholesterol (HDL-C) are components of 
dyslipidaemia. Dyslipidaemia aggravates the atherosclerosis process by leading to lipid 
accumulation on the arterial wall (Garg, Aggarwal, Kumar & Sharma, 2015) and each of its 
components is known to have a certain role in atherosclerotic process.  
Serum TAG were first observed as an essential CV risk factor in the PROCAM study in 1979 
(Assmann & Schulte, 1996) which was further confirmed by Hokanson and Austin (1996), who 
showed in their meta-analysis that fasting TAG are an independent risk factor. Findings of the 
subsequent epidemiological and clinical studies that investigate the relationship between TAG 
and CVD risk suggest that serum levels of TAG may relate to the presence of CV risk (Assmann et 
al., 1998; Jeppesen et al., 1998; Miller et al., 2011; Boullart & Stalenhoef, 2012), however, caution 
should be applied when interpreting their results, given that plasma TAG are highly fluctuating in 
the post-prandial state (Mora, Rifai & Buring, 2008). Furthermore, elevated plasma TAG are 
usually accompanied with low HDL-C (Ginsberg et al., 2007), which may be a confounding factor 
in studies not adjusted for HDL-C. Nevertheless, TAG, as the substrate of LDL-C synthesis, are still 
deemed as a target in clinical management of dyslipidemia and each 1 mmol/l reduction in TAG 





LDL-C, on the other hand, has consistently been found to be directly associated with CVD 
risk in epidemiological studies, human clinical trials and animal studies (Ridker, 2014, Jarcho & 
Keaney, 2016). Discovered almost 30 years ago by Brown and Goldstein (1996), it is now 
considered as the major atherogenic lipoprotein particle due to its direct role in disease 
progression: circulating LDL particles are internalised and then accumulate in the vascular intima 
and once they are oxidised, they convert into foam cells, starting the atherosclerotic process 
(Grooper & Smith, 2013). There is a consensus in the literature that elevated LDL- C is associated 
with increased CVD risk and therefore LDL-C is the primary target of atherosclerosis treatment 
guidelines (Ridker, 2014). Further discussed by Cannon et al. (2015) is whether ‘lower is better’, 
given that a recent major clinical trial named IMPROVE-IT (n=18,144) has revealed a statistically 
significant decrease in CV events between two study groups, one of which was treated with a 
lipid-lowering drug alone (median LDL-C= 1.8 mmol/l) and the other with two different lipid-
lowering agents (median LDL-C= 1.4 mmol /l), (hazard ratio, 0.936; 95% CI, 0.89 to 0.99; p=0.016). 
Although the absolute risk difference between two groups is only 2% in this study, this value is 
statistically significant and hence clinically important. Furthermore, the Cholesterol Treatment 
Trialists’ collaborators reported 23% reduction in the risk of major coronary events when LDL-C 
is decreased by 1.0 mmol /l in their meta-analysis of 90,000 subjects in 2005 (Baigent et al., 2005), 
and then further reported 40-50% reduction when LDL-C is decreased by 0.9-1.4 mmol/l in a 
more recent and larger meta-analysis in 2010 involving 170,000 subjects (Baigent et al., 2010). 
Despite the ample evidence that LDL-C is a strong risk factor for CVD, not all CV patients 
have elevated LDL-C levels (Hirayama & Miida, 2012). This is explained by a great number of 





on the type of LDL lipoprotein complexes (Rizzo & Berneis, 2006; Packard, 2006; Berneis & Krauss, 
2002; Packard, Caslake & Shepherd, 2000). Two decades ago, cross-sectional studies reported 
different LDL-C phenotypes in terms of size and density (Lamarche, Lemieux & Despres, 1999), 
phenotype B, also called small&dense LDL-C (sdLDL), being more atherogenic (Hirayama & Miida, 
2012). The reason is they can easily penetrate into the arterial wall due to their small size, and 
their longer circulation time in the blood stream increase their oxidation capacity (Ivanova, 
Myasoedova, Melnichenko, Grechko & Orekhov, 2017). Past evidence has pointed to an 
association between sdLDL and CVD (Austin et al., 1988; Krauss, 2010; Berneis & Krauss, 2002; 
Rizzo & Berneis, 2006) followed by more recent studies strengthening that association, one of 
which is the Frahangam Offspring Study that suggested sdLDL might be a better indicator of CVD 
then LDL-C itself (Ai et al., 2010). Suita Study (Arai et al., 2013) also showed that sdLDL is useful 
in predicting CVD. Subsequently, in the large prospective ARIC study conducted on 11,419 
subjects by Hoogeveen et al (2014), sdLDL predicted CVD risk even for subjects within the desired 
LDL-C levels. Most recently, a study performed in a Chinese population suggests that sdLDL 
correlates to CVD risk by means of carotid artery intima media thickness (Shen et al., 2015). Taken 
together, these findings collectively support the earlier decision by National Cholesterol 
Education Program (2002) which considers predominance of sdLDL as a CVD risk factor. However, 
there seems to be a lack of standardization in the method of measuring sdLDL in terms of particle 
size and concentration in these given studies, which is a shared limitation of the available 
evidence as different methods deliver different results. Furthermore, with significant variations 





Acting conversely to all, HDL-C is responsible for the removal of excess cholesterol from 
peripheral macrophage foam cells in atherosclerotic lesions. (Ganjali et al., 2017). This process is 
also called the reverse cholesterol transport, and has a protective role in the development of 
atherosclerosis. Indeed, epidemiological studies have shown that low HDL-C levels is strongly 
related to increased atherosclerotic CVD risk (Stone et al., 2013). However, this does not 
necessarily mean that a high HDL-C level prevents atherogenesis. Some of the clinical studies like 
ILLUMINATE (Barter et al., 2007), dal-OUTCOMES (Schwartz et al., 2012), AIM-HIGH (AIM-HIGH 
Investigators, 2011), and HPS2-THRIVE (HPS2-THRIVE Collaborative Group, 2013) linking the 
increased levels of HDL-C with CV outcome data has failed in showing a correlation. This may be 
caused by that serum HDL-C levels do not always reflect the cholesterol efflux capacity from cells 
(Khera et al., 2011). Furthermore, HDL-C is recently reported to be a “chameleon-like” protein 
which loses its protective features in oxidation (Fogelman, 2015), while, atherosclerosis is already 
known to be a chronic inflammatory state (Grooper & Smith, 2013). Supportive of this, there are 
individuals that develop atherosclerosis despite having a high serum HDL-C level, therefore, HDL-
C is not anymore deemed as a primary target in treatment of atherosclerosis. (Toth et al., 2013). 
In the recent years, assessment of non–high-density lipoprotein cholesterol (non-HDL-C) 
gained importance as a more relevant target of dyslipidemia therapy given the fact that it 
provides measurement of all atherogenic particles (Rana, Boekholdt, Kastelein & Shah, 2012) that 
a LDL-C measurement typically excludes. There is plenty evidence to support this approach, 
including a meta-analysis of 8 randomized controlled trials that enrolled 62,154 patients, non-
HDL was found to be a better indicator of CVD risk compared to LDL-C (Boekholdt et al., 2012). 





showed that LDL-C (HR: 1.38, 95% CI, 1.09 to 1.73) is less effective as a CVD risk indicator 
compared to non-HDL (HR: 1.42, 95% CI, 1.06 to 1.91) (Angelantonio et al., 2009). As a result of 
these and other supporting evidence (Cui et al., 2001; Ingelsson et al., 2007; Liu et al., 2006; Mora 
et al., 2009), National Lipid Association and National Institute for Health and Care Excellence 
(NICE) suggested non-HDL-C as a superior marker than others in predicting CVD risk (Jacobson et 
al., 2015). 
Lipid Management Therapy 
Worldwide, there are several guidelines on lipid management, four of which are more 
commonly used in clinical practice (Table 1). 
Table 1 Lipid Management Guidelines Used in Clinical Practice 
Organisation Last Update 
American Heart Association/American College of Cardiology (AHA/ACC) 2013 
National Lipid Association  (NLA) 2014 
National Institute for Health and Care Excellence (NICE) 2014 
European Society of Cardiology (ESC) 2016 
 
All these guidelines aim to define certain risk groups and provide instructions for treatment of 
each risk group. There is ongoing debate about AHA/ACC 2013 guideline as all lipid goals have 
been removed in it (Martin et al., 2014; Lopez-Jimenez et al., 2014). NICE and NLA both suggest 
non-HDL as the primary clinical target of lipid management therapy with statins, while ESC states 
LDL-C should be the primary target. All of them jointly emphasise that the HMG-CoA reductase 
inhibitors (statins) use is the gold standard in lipid management therapy given that its clinical 






Dietary Therapy in Lipid Management  
Diet is the most common non-pharmacological therapy for primary and secondary 
prevention of CVD due to the strong evidence showing its relation to CV risk factors, including 
blood lipid profile (Rees et al., 2013). Many studies investigate the effect of dietary changes on 
blood lipids. Backed by A-level evidence, there is a general agreement that reduction in saturated 
fatty acids (SFA) (Mensink, Zock, Kester & Katan, 2003) and trans fat (Mozaffarian, Aro & Willett, 
2009 ) intake result in a decrease in LDL-C and TAG, while limiting alcohol intake (Rimm, Williams, 
Fosher, Criqui & Stampfer, 1999) as well as reducing mono- and disaccharides (Bantle, Raatz, 
Thomas & Georgopoulos, 2000) result in a decrease in TAG. Increase in dietary fibre (Brown, 
Rosner, Willet & Sacks, 1999) and reduction in total carbohydrate (Nordmann et al., 2006) also 
reduce both LDL-C and TAG.  
Fats are the most essential component of dietary therapy in lipid management. Mensink 
et al. (2003) have shown in their large meta-analysis of 60 controlled trials that when energy from 
SFA is increased by 1% (%E), LDL-C increase by 1.6 mg/dL (0.04 mmol/l) while it decreases equally 
when 1% E from SFA is replaced with monounsaturated fatty acids (MUFA). Polyunsaturated fatty 
acids (PUFA) have a greater impact in LDL-C reduction with a 2.0 mg/dL (0.05 mmol/l) reduction 
when 1% SFA is replaced with PUFA. Marine derived omega-3 PUFAs eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) are particularly suggested as cardioprotective and anti-
atherogenic nutrients as a result of the evidence that showed their several favourable effects on 
overall CV health, including their lipid lowering properties (Dessi et al., 2013), both of which are 






Role of omega-3 Fatty Acids in CVD Prevention and Lipid Management 
Since the early studies in Greenland Eskimos, intake of EPA and DHA have been consistently 
shown to have a cardioprotective role (Massaro, Scoditti, Carluccio & Caterina, 2010). Several 
observational and interventional studies associate increased intake of EPA and DHA with reduced 
CV endpoints. One of the proposed mechanisms to justify such beneficial outcomes include lipid 
modifying effect of EPA and DHA, which is also investigated by a great number of trials.  
Effects of omega-3 Fatty Acids on CV Outcomes 
Among numerous studies in the area, two early randomized trials have clearly shown the 
favourable effects of EPA and DHA on CV outcomes. Diet and Reinfarction Trial (DART) assigned 
2,033 men with recent myocardial infraction (MI) to fish oil capsules and has shown to decrease 
CV mortality by 29% over 2 years (Burr et al., 1989). It is followed by GISSI Prevenzione trial in 
1990s, one of the milestones in the evidence that randomized 11,324 participants to 850 mg of 
EPA/DHA/day versus no intervention for 3.5 years (GISSI, 1999). The study showed that fish oil 
consumption was associated with a significant reduction in sudden deaths by 45% (RR 0.55; 95 % 
CI, 0.39–0.77; p = 0.0006) and CV mortality by 30% (RR 0.69; 95 % CI, 0.66–0.93; p = 0.006). Both 
DART and GISSI trials continued as the second phases, however DART 2 (n = 3,114) showed 
conflicting results (Burr et al., 2003) due to several limitations in the experimental design such as 
lack of blinding, eating advice to the control group and early interruption that make it difficult to 
interpret the findings. GISSI-Heart Failure (GISSI-HF), on the other hand, was a large (n = 6,975), 
randomized placebo-controlled trial that assessed the association between heart failure and 





cause mortality was observed in the intervention group (HR 0.91; 95.5 % CI, 0.833–0.998; p = 
0.041). 
After 2010s, further RCTs followed up on the initial positive findings of DART and GISSI trials, 
albeit with conflicting results. These studies are summarised in Table 2. 
Table 2 Most recent randomized controlled trials of OM-3 FA and CVD risk 
Name & Author Size & Inclusion 
Criteria 





(Kromhout, Giltay & 
Geleijnse, 2010) 
n=4,837  
history of past 
MI 
376 mg/day EPA&DHA vs. a 
combined control group 
receiving either placebo or 
ALA 1.9 g/day 
3.7 Major CV events n =671  




(Rauch et al., 2010) 
n=3,851  
recent MI 
840 mg/day EPA&DHA vs. 
placebo 
1 Major CV events n =331 
(HR 1.21; 95% CI, 0.96–1.52) 
SU.FOL.OM3 
 
(Galan et al., 2010) 
n=2,501  
history of acute 
coronary event 
600 mg/day EPA&DHA vs. a 
combined control group 
receiving either placebo or B 
vitamins 
4.7 Major CV events n =157 









1 g/day EPA&DHA and 
insulin glargine vs. 1 g/day 
olive oil placebo and 
standard glycemic care 
6.2 Sudden Death n=574  
(HR 0.98; 95% CI, 0.87–1.10; 
p=0.72). 
Risk and Prevention  
 
(The Risk and Prevention 
Study Collaborative Group, 
2013) 
n=12,513 
high CVD risk 
without 
previous MI 
1 g/day EPA & DHA vs. olive 
oil placebo 
5 Sudden Death or CV hospitalization  
n =733 
(HR 0.98; 95 % CI, 0.88–1.08; 
p=0.64) 
Notes: MI: Myocardial Infraction, ALA: Alpha Linoleic Acid, HR: Hazard ratio, CI: Confidence interval 
Nevertheless, caution should be applied when interpreting these studies, as they have 
certain limitations. Alpha-Omega trial prescribed only 0.37g/day EPA&DHA, which is much less 
than the dose given in all other previous studies, and also compared the results not with placebo 
but with a combined control of either placebo or n-3 ALA. Omega and SU.FOL.OM3 trials were 





power of 0.17 and 0.14 respectively (CV death: Omega n=57, SU.FOL.OM3 n=40). The Origin trial 
was designed for a dysglycemic population and used n-3 FA together with insulin therapy, thus 
possibly prevented measureable effects of n-3 supplementation. Finally, the authors of Risk and 
Prevention trial acknowledge that lower than expected rates of CV endpoints is a limitation of 
their study, possibly due to the Italian cohort already on a healthy dietary pattern, accompanied 
by intensive preventive care during the 5 year follow-up period. 
Supportive of the early results from DART and GISSI trials, numerous meta-analysis of 
smaller scale RCTs collectively report a negative association between EPA&DHA intake and risk 
of CV mortality (Mozaffarian & Rimm, 2006; Mente , Koning, Shannon & Anand, 2009; Wang et 
al., 2006; Brouwer et al., 2009; Harris et al., 2009; He et al., 2004; Hooper et al., 2004; Hooper et 
al., 2006; Leon et al., 2008; Marik & Varon, 2009) 
Besides these given studies, JELIS trial, another large (n=18,645) and high-quality 
intervention study on a Japanese population, has shown a significant 19% relative reduction in 
major coronary events between the groups (Yokoyama et al., 2007). Designed differently, all 
participants were on statin prescription and the study compared statin monotherapy to a 
combination of 1.8g/day EPA plus statin. Similar favourable effects of combination therapies will 
be discussed later on in this chapter. 
Overall, the evidence shows that a higher intake of EPA and DHA results in a reduced risk 
of CVD. Proposed mechanisms to justify these beneficial outcomes include lipid modifying effects 






Effects of omega-3 Fatty Acids on Lipids and Lipoproteins  
Published guidelines reviewed in Table 1 emphasize the use of statins as primary 
treatment strategy for dyslipidemia. However, evidenced shows that patients who cannot use 
statins, or those who need additional lipid-lowering therapy can use omega-3 FA, especially EPA 
and DHA, either alone or in combination with statins for management of dyslipidemia. Suggested 
mechanism of action of these FA involves inhibition of TAG synthesis in hepatic cells, reduced 
very LDL-C (VLDL-C) production as well as increased VLDL-C metabolism (Bradberry & Hilleman, 
2013). 
Major clinical trials that examined the effects of EPA and DHA on blood lipids have shown positive 
results (Table 3).  
Table 3  Major clinical trials about the role of EPA&DHA monotherapy on blood lipids 
Name & 
Author 











fasting TAG≥5.7 mmol/l 










1)OM-3 2 g/day (n=100) 
2) OM-3 3 g/day (n=101) 
3) OM-3 4 g/day (n=99) 
4) control (placebo) (n=99) 
 
(34% of the subjects were 
using statin as prescribed) 
12 weeks TAG ↓ 
2 g: −26%, p < 0.01  
3 g: -25%, p < 0.01 
4 g: −31%, p<0.001 
 
Non-HDL-C ↓ 
2 g: −8%, p < 0.05  
3 g: -7%, p < 0.05 
4 g: −10%, p<0.01 
 
HDL-C no sig. change 
LDL-C ↑ 
2 g: 19%, p < 0.01  
4 g: 19%, p<0.001 
 
VLDL-C ↓ 
2 g: −27%, p < 0.01  
3 g: -25%, p < 0.01 



















fasting TAG≥5.7 mmol/l 
and <22.5 mmol/l 
 






1)EPA 2 g/day (n=76) 
2) EPA 4 g/day (n=77) 
4) control (placebo) (n=76) 
 
 TAG ↓ 
2 g: −20%, p < 0.005 
4 g: −33%, p<0.0001 
 
Non-HDL-C ↓ 
2 g: −8%, p < 0.05  
4 g: −18%, p<0.0001 
 
HDL-C & LDL-C no sig. change 
 
VLDL-C ↓ 
2 g: −15%, p < 0.05 
4 g: −29%, p<0.001 
 
LDL-C particle concentration  ↓ 
Notes: ↓ reduction, ↑ increase, r/i: run in,  
Backed by ample evidence, EPA & DHA monotherapy is commonly used for treating 
hypertriglyceridemia (HTG). In presence of very high TAG levels (≥500 mg/Dl; 5.7mmol/l), 
EPA&DHA 2 g/day to 4/day is shown to reduce TAG by 25% to 45% depending on the baseline 
TAG levels (Weintraub, 2014; Harris et al., 1997). Similarly in EVOLVE, MARINE, ORIGIN and Risk 
and Prevention studies, the plasma TAG levels were significantly reduced (Table 2 & Table 3). In 
a systematic review and meta-analysis of 21 randomized controlled trials [n=7803] of the effect 
of EPA&DHA supplementation on blood lipids, a net reduction of 0.3 mmol/l (−0.4, −0.2, 
P<0.0001) was reported in blood TAG (Balk et al., 2006). Similarly, a comprehensive meta-analysis 
of 47 studies that compare the effects of EPA&DHA on blood lipids with placebo showed that 
TAG is reduced by 0.07 mmol/l over an average treatment period of 24 weeks in 16,511 subjects 
with hyperlipidemia (Eslick, Howe, Smith, Priest & Bensoussan, 2009). 
LDL-C, however, is usually reported to rise on EPA&DHA treatment, possibly due to 





their systematic review a 0.2 mmol/l (+0.08, +0.2, P= 0.0006) increase in LDL-C levels. In EVOLVE 
trial, LDL-C increased 19% (p<0.001) with 2g/day and 4 g/day EPA&DHA intake.  
HDL-C increased +13% (p = 0.014) with 4 g/day EPA&DHA in a 4-months study on subjects 
with TAG ≥5.7 mmol/l (Harris et al., 1997) and Balk et al. (2006) reported in their review a 0.02 
mmol/l (+0.01, +0.03, P= 0.0003) statistically significant increase. In a 6-weeks study there was 
only a non-significant 5.9% (p = 0.057) increase (Pownall et al., 1999).  
LDL-C and HDL-C did not significantly change in all studies. Eslick et al. (2009), for instance, 
observed no clinically significant benefit for HDL-C (+0.05 mmol/l, 95% CI: 0.00 to 0.36) and no 
increase in LDL-C (+0.03 mmol/l, 95% CI: 0.54 to 1.62). Similarly, the Risk and Prevention Study 
reports a slight increase in the HDL level in the intervention group and no significant difference 
in LDL-C, while EVOLVE reports no significant increase in HDL-C. MARINE trial also reports no 
significant changes in HDL-C and LDL-C. Such slight changes or no change in HDL-C and LDL-C 
could be due to the combined use of EPA and DHA in these studies, given that these two fatty 
acids show reverse characteristics in LDL-C and HDL-C alteration. A recent review which 
evaluated 22 studies that either compare EPA with DHA or investigate EPA or DHA alone suggests 
that EPA and DHA may have distinct effects on blood lipids (Jacobson, Glickstein, Rowe & Soni, 
2012).  DHA is reported to have a stronger role in increasing LDL-C with a net increase of 3.3% in 
head-to-head comparative studies. Same sub-group analysis shows that DHA is associated with 
a 6.8% net decrease in TAG and a net increase in HDL-C by 5.9%. Furthermore, in 70% of DHA-
alone studies, LDL-C is observed to increase as opposed to EPA alone studies all of which showed 
a decrease in LDL-C. HDL-C, on the other hand, is observed to increase in 85% of DHA-alone 





remarkable, further studies are required to have a clear understanding of the distinct 
mechanisms of EPA and DHA that affect HDL-C and LDL-C alteration. 
Although a number of studies report an increase in LDL-C after fish oil use, TAG reduction 
is more significant than the increase in LDL-C in subjects with mild to moderate HTG (Pirillo & 
Catapano, 2013). More importantly, the rise in LDL-C due to EPA and DHA is caused by a shift 
from small&dense LDL-C to large & buoyant LDL phenotype, therefore reducing the risk of 
atherosclerotic CVD (Jacobson, 2008; Woodman et al., 2003; Calabresi, Donati, Pazzucconi, Sirtori 
& Franceschini, 2000). This is further confirmed by the MARINE trial (Bays et al., 2011) as well as 
a meta-analysis and systematic review of 24 RCTs (n=1533) which also shows that LDL-C increase 
3% with a concomitant change in particle size (Hartweg, Farmer, Holman & Neil, 2009). In 
addition to the possible improvement in LDL-C phenotype, EPA&DHA monotherapy also resulted 
in significant decreases in non-HDL-C in both MARINE and EVOLVE trials. 
Overall, EPA and DHA monotherapy may result in an improved lipid and lipoprotein profile 
as a result of their role in reducing TAG and non-HDL-C as well as shifting to a large & buoyant 
LDL-C from sdLDL-C. However, clinical trials have shown that EPA and DHA supplementation is 
more effective when combined with other lipid-lowering drugs - mostly statins (Pirillo & 
Catapano, 2013). 
Combination Therapies: Statin and Omega-3  
Although statins are considered as the first choice in lipid management therapy in all 
clinical guidelines (Table 1) in cases when elevated lipid levels are persistent to statin, 





LDL-C particle size (Kastelein et al., 2014). Several clinical trials have shown that blood lipids of 
dyslipidemic patients respond favorable to EPA&DHA/statin combinations (Table 4). Addition of 
EPA & DHA resulted in significant further reductions in TAG compared to statin therapy alone in 
most of the past combination trials (Contacos, Barter & Sullivan, 1993; Mataki et al., 1998; 
Durrington et al., 2001; Chan et al, 2002; JELIS; Davidson, et al., 2007; Maki et al., 2013, Chan et 
al., 2016). A range of 9% to 55% reduction in plasma TAG have been observed, in most cases with 
a reduction of 30% and above (Table 4). HDL-C, on the other hand, is shown to increase with a 
combination therapy in some studies (Nordøy, Hansen, Brox & Svensson, 2001; Chan, 2002; 
Davidson, et al., 2007; Maki et al., 2008), whereas in others it has remained unchanged 
(Contacos, Barter & Sullivan, 1993; Nordøy et al., 1998; Mataki et al., 1998; Durrington et al., 
2001; Chan et al., 2016). It is therefore difficult to reach a conclusion about the role of n-3 and 
statins in altering HDL-C out of the results of past trials. When endogenous cholesterol synthesis 
is inhibited, EPA&DHA supplementation may have a role in decreasing total cholesterol without 
increasing LDL-C cholesterol (Nordoy, 1998). Supportive of this, combination of EPA&DHA with 
statins counteracted the expected increase in LDL-C due to n-3 use (as seen in monotherapies in 
Table 3), hence no significant increase in LDL-C was observed in any of the combination trials 
listed in Table 4. On the contrary, small&dense LDL-C particles significantly decreased with the 
combined use of EPA&DHA with statin in trials that had measured LDL-C particle size and 
concentration (Contacos, Barter & Sullivan, 1993; Nordøy, Hansen, Brox & Svensson, 2001; Maki 
et al., 2008). The decrease in VLDL-C and chylomicrons with EPA&DHA was resulted in a 
significant decrease in atherogenic particles, therefore 10-20% significant reductions in non-HDL-





The past evidence of combination trials is limited. Furthermore, most of the studies 
recruited a small number of participants (less than 100) with an average duration of 6-8 weeks. 
Exemptions of this are the JELIS, COMBOS and ESPIRIT studies, all showing promising results for 
further research in the area. JELIS, the largest combination trial conducted to date (n=18,645), 
showed not only improvement in certain blood lipids, but also a 19% reduction in major coronary 
events (p<0.001) attributed to EPA treatment. However, this study was not double-blind. 
Completed by Davidson et al. in 2008, COMBOS trial (n=254) is the first study that showed an 
improvement in all measured lipid parameters (non-HDL-C, TC, TAG, HDL-C, VLDL-C). Maki et al. 
(2008) extended Davidson et al.’s study and reported an improvement also in LDL-C particle size 
when EPA&DHA and statins are combined. However, Bays et al. (2010), Ballantyne et al. (2012), 
Maki et al. (2013) and Chan et al. (2016), who all tested the efficacy of EPA&DHA with statin and 
reported positive results, did not measure LDL-C particle size and concentration in their studies 





Table 4 Randomized controlled trials of combined therapy of OM3-FA and statin (continued to page 33) 
 
Name & Author Inclusion Criteria Size Research Design Results 
Contacos, Barter & Sullivan, 1993 
Effect of pravastatin and omega-3 
fatty acids on plasma lipids and 
lipoproteins in patients with 
combined hyperlipidemia 
 
TC >5.5 mmol/l  
TAGs  >5.7 
mmol/l 
32 Dietary r/i= 6 weeks 
 
1st intervention6 weeks 
3 groups 
1) 3 g/day 
EPA&DHA 2:1 (n=10) 
2) 40 mg/day statin (n=10) 
3) placebo (n=10) 
 
2nd intervention 
12 weeks (n=31) 
3 g/day 
EPA&DHA 2:1  + 40 mg/day statin  
 
1st intervention 
In statin group:  
TC ↓ 23% p<.001 
LDL-C ↓ 30% p<.001 
LDL-C particle size no change 
In n-3 group: 
TAG↓ 30% p<.05 
LDL-C particle size ↑ p<.05 
LDL-C ↑ 13%  p>0.05 
VLDL-C  ↓ 37% p<.05 
 
2nd intervention 
In statin+comb group:  
TAG↓ 33% p<.05 
LDL-C ↑ 10% p <.01 
LDL-C particle size no change 
In n-3+comb group: 
TC ↓ 18%; p<.01 





Name & Author Inclusion Criteria Size Research Design Results 
In placebo+comb group: 
TC ↓ 25% p<.001 
TAG ↓33% p<.05 
LDL-C ↓ 26% p ><.01 
Nordøy et al., 1998 
Effects of simvastatin and omega-3 
fatty acids on plasma lipoproteins 
and lipid peroxidation in patients 
with combined hyperlipidaemia 
 
TC >5.3 mmol/l 
TAG >2.0 mmol/l 
 <15.0 mmol/l 
41 Dietary r/i= 16 weeks 
 
1st intervention 
5 weeks, 2 groups: 
1) statin 20mg/day (n=20) 
2) placebo (n=20) 
 
2nd intervention5 weeks 




5 weeks, 2 groups: 
1) 4g/day EPA&DHA + 20 mg/day statin 
(n=22) 
2) placebo + 20 mg/day statin (n=20) 
 
In n-3 group: 
TC ↓ 10% p=.052 
TAG↓ 55% p<.001 
LDL-C no change p=0.4 









Name & Author Inclusion Criteria Size Research Design Results 
Mataki et al., 1998 
Effect of eicosapentaenoic acid 
in combination with HMG-CoA 
Reductase Inhibitor on lipid 
metabolism 
 
N/A N/A No dietary r/i 
 
1st intervention12 weeks 
1 group: 
1.8g/day EPA+ 5-10 mg/day statin 
(n=N/A) 
 
2nd  intervention12 weeks 
1 groups: 
5-10 mg/day statin (n=N/A) 
1st intervention 
TC ↓ 20% p=N/A 
TAG↓ 40% p=N/A 
LDL-C & HDL-C no change p=N/A 
 
2nd Intervention 
TC ↓ 1% p>.05 
TAG ↑ 50% p=N/A 
 
Durrington et al., 2001 
An omega-3 polyunsaturated fatty 
acid concentrate administered for 
one year decreased triglycerides in 
simvastatin treated patients with 
coronary heart disease and 
persisting hypertriglyceridemia. 
 
TAGs  >2.3 
mmol/l  
on statin 
59 No dietary r/i 
1st intervention 
24 weeks, 2 groups: 
1) 4g/day EPA&DHA + 10-40 mg/day 
statin  
(n=30) 
2) placebo + 10-40 mg/day statin (n=29) 
 
2nd intervention= 24 weeks, 1 
group(n=46) 
4g/day EPA&DHA+ 10-40 mg/day statin 
  
1st intervention 
In n-3 group: 
TAG ↓25% p<.0005 
TC ↓10% p<.025 
LDL-C & HDL-C no change 
Non-HDL ↓10% p=not given 
VLDL ↓ 40% p<.005 
 
2nd intervention 
In n-3 group: 





Name & Author Inclusion Criteria Size Research Design Results 
TC further ↓ 2% p<.005 
LDL-C ↓ 15% p<.025 
HDL-C no change 
Non-HDL further ↓2% p=not given  
 
In placebo group: 
TAG ↓25% p<.0005 
VLDL ↓25% p<.005 
HDL-C, LDL-C, TC, non-HDL no change 
Nordøy, Hansen, Brox & Svensson,  
2001 
Effects of atorvastatin and omega-3 
fatty acids on LDL subfractions and 
postprandial hyperlipidaemia in 
patients with combined 
hyperlipidaemia. 
 
TC >5.3 mmol/l 
TAG  >2.0 mmol/l 




42 Dietary r/i= 12 weeks 
 
1st intervention5 weeks 
1 group (n=42) 





1) 1.68 g/d EPA&DHA + statin (n=22) 
2) placebo + statin (n=20) 
 
1st intervention 
TAG ↓25% p<.05 
TC ↓30% p<.01 
LDL-C ↓35% p<.01 




HDL ↑ 10% p=.03 
s&d LDL↓ p<.05 
postprandial TAG ↓ p < 0.01 





Name & Author Inclusion Criteria Size Research Design Results 
Chan, 2002 
Factorial study of the effects of 
atorvastatin and fish oil on 
dyslipidaemia in visceral obesity. 
Obese (BMI>29) 
LDL >2.6 mmol/l 
Non-HDL>3.4 
mmol/l 
TAGs  >1.2 
mmol/l 





1) 40 mg/day statin + placebo 
(n=13) 
2) 4g/day EPA&DHA+ placebo 
(n=12) 
3) 4g/day EPA&DHA + 40 mg/day statin 
(n=11) 





TAG ↓ 0.38 ±0.11 mmol/L  P= 0.002 
HDL-C ↑ +0.07 ± 0.04 mmol/L P= 0.041 
LDL-C no change 
 
 
Yokoyama et al., 2007 (JELIS) 
Effects of eicosapentaenoic acid on 
major coronary events in 
hypercholesterolaemic patients 
(JELIS): a randomised open-label, 
blinded endpoint analysis  
TC >6.5 mmol/l 
LDL-C>4.5 mmol/l 
18,645 r/i= 4-8 weeks 
1st intervention 
5 years, 2 groups 
1) 1.8 g/day EPA + 10-40 mg/day statin 
(n=9326) 
2) 5-10 mg/day statin 
(n=9319) 
Clinical benefit of combination therapy with omega-3 
fatty acids and statin has been reported 
EPA treatment was associated with a 19% ↓ in major 
coronary events p<0.001 
n-3 group: 
TAG ↓9% p<.05  
TC ↓19% p<.001 





Name & Author Inclusion Criteria Size Research Design Results 
 HDL-C ↑ 3%   
control group 
TAG ↓3% p<.05  
TC ↓19% p<.001 
LDL-C ↓25% p<.001 
HDL-C ↑ 4%   
Davidson, et al., 2007 (COMBOS) 
Efficacy and tolerability of adding 
prescription omega-3 fatty acids 4 
g/d to simvastatin 40 mg/d in 
hypertriglyceridemic patients: an 8-
week, randomized, double-blind, 
placebo-controlled study. 
 
TAG levels >2.3 
and 
<5.7 mmol/l 
LDL >10% ATPIII 
254 8 week r/I with 40mg/day statin 
 
1st intervention 
8 weeks, 2 groups 
 
1) 4g/day EPA&DHA + 40 mg/day statin 
(n=123) 
2) 40 mg/day statin + placebo (n=133) 
 
n-3 group: 
non-HDL-C ↓9% p<.001  
TC ↓4.8 p=.001 
TAG ↓30% p<.001 
VLDL-C ↓28% p<.001 
HDL-C ↑ 3.4%  p<.001 
LDL-C ↑ 0.7%  p=.052 
 
control group 
non-HDL-C ↓2.2% p<.001  
TC ↓1.7 p=.001 
TAG ↓6% p<.001 
VLDL-C ↓7% p<.001 
HDL-C ↑ 1.2%  p<.001 





Name & Author Inclusion Criteria Size Research Design Results 
Maki et al., 2008 
Effects of Adding Prescription 
Omega-3 Acid Ethyl Esters to 
Simvastatin (20 mg/day) on Lipids 
and Lipoprotein Particles in Men and 
Women With Mixed Dyslipidaemia  
 
TAG levels >2.3 
and 
<6.7 mmol/l 
Non-HDL> NCEP  






1) 4g/day EPA&DHA + 20 mg/day statin 
(n=123) 




2 groups (cross-over) 
 
1) 4g/day EPA&DHA + 20 mg/day statin 
(n=123) 
2) 20 mg/day statin + placebo (n=133) 
 
n-3 group: 
Non-HDL↓ 40% p<.001 
VLDL-C ↓ 42% p<.05 
TAG ↓44% p<.05 
TC ↓31 p<.05 
HDL-C ↑ 16%  p<.05 
LDL-C ↓37 p>.05 
sLDL ↓ 2% p<.05 
 
control group 
Non-HDL↓ 34% p<.001 
VLDL-C ↓ 22%  p<.05 
TAG ↓29% p<.05 
TC ↓26 p<.05 
HDL-C ↑ 11%  p<.05 
LDL-C ↓40 p>.05 
sLDL ↓1% p<.05 
Bays et al., 2010 
Effects of prescription omega-3-acid 
ethyl esters on non-high-density 
lipoprotein cholesterol when 
  n-3 vs statin  n-3 group: 
Non-HDL↓ 40% p<.001 
VLDL-C ↓ 54% p<.001 





Name & Author Inclusion Criteria Size Research Design Results 
coadministered with escalating 
doses of atorvastatin. 
 
 
TC ↓31 p=.002 
HDL-C ↑ 12%  p=.007 
LDL-C no sig. difference 
control group 
Non-HDL↓ 34% p<.001 
VLDL-C ↓ 37%  p<.001 
TAG ↓27% p<.001 
TC ↓27 p=.002 
HDL-C ↑ 10%  p=.007 
LDL-C no sig. difference 
Vecka et al., 2012 
N-3 polyunsaturated fatty acids in 
the treatment of atherogenic 
dyslipidemia.  
 




56 n-3 vs statin TAG ↓28% p<.001 
VLDL-C ↓ 27%  p<.001 
HDL-C ↑ 4%  p<.01 
LDL-C ↑9 p<.01  
Ballantyne et al., 2012 (ANCHOR) 
Efficacy and safety of 
eicosapentaenoic acid ethyl ester 
(AMR101) therapy in statin treated 
patients with persistent high 
triglycerides (from the ANCHOR 
study). 










1)2 g/day EPA + statin 
TAG ↓ 
2 g: −10%, p = 0.0005  
4 g: −21%, p<0.0001 
Non-HDL-C ↓ 
2 g: −6%, p = 0.0054 






Name & Author Inclusion Criteria Size Research Design Results 
2)4 g/day EPA + statin 
3)placebo + statin 
HDL-C ↓ 
4 g: −5%, p<0.01 
LDL-C ↓ 
4 g: −6%, p=0.006 
VLDL-C  
2 g: −10%, p < 0.01  
4 g: −25%, p<0.0001 
Maki et al., 2013 (ESPRIT) 
A highly bioavailable omega-3 free 
fatty acid formulation improves the 
cardiovascular risk profile in high-
risk, statin-treated patients with 
residual hypertriglyceridemia (the 
ESPRIT trial) 
 











1) 2g/day EPA&DHA + statin (n=215) 
2)4g/day EPA&DHA + statin (n=216) 





2 g: −15%, p < 0.01  
4 g: −21%, p<0.01 
Non-HDL-C ↓ 
2 g: −4%, p < 0.05  
4 g: −7%, p<0.01 
LDL-C ↑ 
2 g: 4.6%, p < 0.05  
VLDL-C ↓ 
2 g: −14%, p < 0.01  







Name & Author Inclusion Criteria Size Research Design Results 
Chan et al., 2016 
Effect of omega-3 fatty acid 
supplementation on arterial 
elasticity in patients with familial 
hypercholesterolaemia on statin 
therapy 
 
(DLCN) score >8 
(definite FH) 
BMI< 40 k/m2  






1) 4g/day EPA&DHA + statin (n=123) 




2 groups (cross-over) 
n-3 group: 
Non-HDL↓ 10% p=.09 
TAG ↓20% p=.01 
TC ↓9  p=.06 
LDL-C ↓10  p=.2 
HDL-C ↓ 6%  p=.5 
 






CV benefits of omega-3 fatty acids are well-documented by several studies. Large clinical 
trials have shown reduced CV events and reduced CV risk with sustained intake of marine-derived 
OM-3 FA EPA&DHA. These fatty acids have been also demonstrated to beneficially alter the blood 
lipid profile in subjects with dyslipidemia – which is one of the known causes of atherosclerosis. 
Although clinical guidelines endorse statin use in management of lipid-related problems, 
accumulating clinical data suggest that marine-derived n-3 fatty acids EPA&DHA significantly 
reduce blood TAG and VLDL-C when used without another lipid lowering agent. An increase in 
LDL-C levels may be expected with EPA&DHA monotherapy, however, when combined these 
fatty acids are combined with statins, this effect is usually counter balanced. Studies that 
compare statin monotherapy with n-3 combination therapies collectively show added benefits 
on blood lipid profile and conclude that EPA&DHA enhance statin-mediated improvements. 
When EPA&DHA is administered in combination with statin, significant benefits are achieved 
among a range of lipid parameters beyond LDL-C primary target. Such achievements include a 
range of 30 to 55% reductions in TAG, as well as 10-20% reductions in non-HDL. More 
importantly, in the limited number of the clinical trials that have monitored the changes in size 
and concentration of LDL-C particles with OM-3 FA use, significant reductions in small and dense 
LDL-C particles, a possibly more important predictor of future cardiovascular risk than LDL-C 
alone, have been reported. The hypothesis that sustained high-dose EPA&DHA intake could alter 
LDL-C particle phenotype can be drawn on the findings of these studies, however, additional 
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Journal Decision  
This work would potentially be published in Atherosclerosis journal. Atherosclerosis brings 
together papers that concern “arterial and vascular biology and disease, as well as their risk 
factors including: disturbances of lipid and lipoprotein metabolism, diabetes and hypertension, 
thrombosis, and inflammation”. According to the 2016 Web of Science citation reports, 
Atherosclerosis has an impact factor of 4.239 and ranks 37 in the field of Cardiac & Cardiovascular 
Systems. Having 9 similar clinical studies published in the past 5 years, Atherosclerosis seems to 


















Background: Epidemiological and clinical evidence suggests that high-dose intake of long-chain 
OM-3 FA have a favourable role in altering blood TAG and non-HDL-C when combined with statins 
in hyperlipidemic patients. Their efficacy in altering LDL-C particle size and concentration is yet 
to be confirmed.  
Aim: This study evaluated the effects of adding 4/day EPA+DHA to stable statin therapy on non-
HDL-C,  TAG, HDL-C, LDL-C and small&dense LDL-C particle concentration in a group of 
hyperlipidemic patients.  
Methods: In this randomized, placebo-controlled, double-blind parallel group study, 44 subjects 
who were already on statin therapy for >8 weeks and had non-HDL-C levels above the National 
Lipid Association Recommendations were randomized into two groups. For 8 weeks, together 
with their prescribed atorvastatin, the intervention group received 4 g/day EPA+DHA (in ethyl 
ester form) while the control group received 4 g/day olive oil (placebo). Baseline measurements 
of non-HDL-C, TAG, TC, HDL-C, LDL-C, VLDL-C and LDL-C particle concentration were repeated at 
week 8. Differences in dietary intake was assessed with a weighted 3-day food diary at week 4. 
Primary outcome measures were the percent change in LDL-C III non-HDL-C and particle 
concentration from baseline. 
Results: At the end of treatment, the median percent change in LDL-C III particle concentration 
was significantly greater with OM-3 FA plus atorvastatin compared with placebo plus atorvastatin 
(-67.5% vs -0%, respectively; P <0.001). OM-3 FA plus atorvastatin was associated with significant 
reductions in non-HDL-C (-9.5% vs 4.7%, P<0.01), TAG (-21.5% vs 6.2%, P <0.001) and VLDL-C (-





difference in percent change in LDL-C, HDL-C, as well as LDL-C I and LDL-C II particle concentration 
was observed.  
Conclusion: In these adult, white patients with hyperlipidemia, P-OM3 plus atorvastatin 
improved LDL-C phenotype, non-HDL-C and other lipid and lipoprotein parameters to a greater 
extent than atorvastatin alone. 
 
Introduction  
Hyperlipidemia, is one of the known etiological causes of atherosclerosis (Julius, 2017). 
Epidemiological studies have shown that elevated serum levels of triglycerides (TAG) and low 
density lipoprotein cholesterol (LDL-C) as well as low levels of high density lipoprotein cholesterol 
(HDL-C) are independently and partially linked to the development of atherosclerosis (Garg, 
Aggarwal, Kumar, & Sharma, 2015). Although much focus has been on LDL-C as the primary 
therapeutic target of atherosclerosis, recent National Lipid Association guideline (Jacobson et al., 
2015) suggest that non-high density lipoprotein cholesterol (non-HDL-C) might be a superior 
indicator of cardiovascular disease risk (CVD) than LDL-C is, based on immense clinical evidence 
(Boekholdt et al., 2012). More importantly, LDL-C phenotype is also suggested to be an important 
determinant of atherosclerotic process. Small and dense LDL-C particles have an increased 
capacity to penetrate into the arterial wall and are more readily oxidized compared to the large 
and buoyant ones (Ivanova, Myasoedova, Melnichenko, Grechko & Orekhov, 2017). Consistent 
with this, clinical studies collectively show a positive relation between serum concentration of 
small&dense LDL-C particles and CVD risk (Austin et al., 1988; Krauss, 2010; Berneis & Krauss, 





Although statins are the first drug of choice to alter blood lipids, accumulating evidence 
suggests that marine-derived omega-3 fatty acids (OM-3 FA) eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) have a capacity to treat hyperlipidemia (Massaro, Scoditti, Carluccio 
& Caterina, 2010). High-dose EPA&DHA supplementation effectively decreased plasma 
triglycerides and non-HDL-C in several clinical studies. In two large clinical trials EVOLVE (n=399) 
(Kastelein et al., 2014) and MARINE (n=229) (Bays et al., 2011), 4g/day EPA&DHA 
supplementation alone resulted in 31 %( p<0.001) and 33% (p<0.0001) reduction in serum TAG 
as well as 10% (p<0.01) and 18% (p<0.0001) reduction in non-HDL-C, respectively. LDL-C, 
however, is usually reported to rise on EPA&DHA treatment, possibly due to increased 
production of LDL-C from VLDL-C (Pirillo & Catapano, 2013). Balk et al. (2006) reported in their 
systematic review a 6 mg/dL (+3, +8, P= 0.0006) increase in LDL-C levels. In the EVOLVE trial, LDL-
C increased 19% (p<0.001) with 4 g/day EPA&DHA intake. The increase in LDL-C with EPA&DHA 
monotherapy, however, is usually counter balanced when these fatty acids are combined with 
statins (Nordoy et al., 1998). Indeed, clinical trials that compare statin monotherapy with n-3 
combination therapies collectively show added benefits on blood lipid profile and conclude that 
EPA&DHA enhance statin-mediated improvements, with a range of 30 to 55% reductions in TAG, 
as well as 10-20% reductions in non-HDL-C without concomitant increase in LDL-C (Davidson et 
al., 2007; Maki et al., 2013, Bays et al., 2010; Ballantyne et al, 2012). In COMBOS trial (n=254), 
4g/day EPA+DHA supplementation combined with simvastatin resulted in 10% reduction in non-
HDL-C (p<.001) with no accompanying increase in LDL-C (Davidson et al., 2007), while the same 
study design in ESPRIT trial (n=647) showed 7% decrease in non-HDL-C (p<0.01) with no 





As opposed to the great number of clinical studies that investigate the role of OM-3 FA in 
altering blood lipids, their effect on LDL-C particle size and concentration has not been widely 
investigated. Nordøy, Hansen, Brox & Svensson (2001) reported a significant decrease in LDL-C 
particle size (p<.05) when 1.68 g/d EPA&DHA is combined with statin, despite the relatively low-
dose of OM-3 FA supplements. Similar results are reported by Maki et al. (2008) with 4g/day 
EPA+DHA combination therapy with statin. Subsequent studies that tested the efficacy of 
EPA&DHA with statin and reported positive results did not measure LDL-C particle size and 
concentration in their studies despite these earlier findings (Bays et al., 2010; Vecka et al., 2012; 
Ballantyne et al., 2012; Maki et al., 2013; Chan et al., 2016). 
In the present study, the efficacy of dietary supplementation with 4 g/day EPA+DHA to 
statin therapy for lowering non-HDL-C and small&dense LDL-C particle concentration in statin 
treated hyperlipidemic subjects was investigated. This study was approved by the University of 
Chester Faculty of Clinical Sciences and Medicine Research Ethics Committee (REF: 
1288/17/GD/CSN) (Appendix I: Ethical Approval). 
Methods 
Participants  
Eligible participants were Caucasian men or women aged between 50 and 79 years who had been 
receiving a stable dose of atorvastatin for the control of LDL-C levels at least for 8 weeks before 
initial screening. Inclusion criteria was current combined hyperlipidemia with a non-HDL-C level 






Table 5 NLA Treatment goals for non–HDL-C, LDL-C in mg/dL 
 Treatment Goal 
Risk category Non-HDL-C LDL-C 
Low 130 100 
Moderate 130 100 
High 130 100 
Very-high 100 70 
 
Exclusion criteria included current use of OM-3 supplements, recent history of certain 
heart, kidney, liver, or cancer (patients that have had any type of heart surgery, patients that are 
diagnosed with any type of cancer and/or have had any kind of cancer therapy, patients that have 
had kidney failure, patients that have had liver failure) in the past 6 months, as well as ongoing 
pregnancy or lactation. All subjects were asked to give a signed informed consent (Appendix II: 
Informed Consent) before study-protocol was conducted. 
Recruitment 
100 patients who had been prescribed to atorvastatin for more than 8 weeks were invited for 
the initial screening, during which their serum LDL-C was measured. 38 of them did not meet the 
inclusion criteria, and 12 eligible subjects did not give consent to take part in the intervention. 44 
subjects, out of the remaining 50, were randomly recruited for the study. The random sampling 
was done via www.randomizer.com. 
Study Design 
This was a randomized, double-blind, placebo controlled, parallel groups study. Figure 1 
summarizes the trial design. Before entry into the intervention phase of the study, 8-weeks of 





to maintain this diet throughout the study. Adherence to dietary advice was measured by a 3-
days weighted food diary at Week 4. Nutrient content of the diet was calculated with Nutritics 
software (Nutritics Ltd, Ireland) using UK: SACN 2015 food composition tables. 
Figure 1 Study Flowchart 
After dietary lead-in, baseline measurements of fasting blood Triglycerides (TAG), Total 
Cholesterol (TC), High-density Lipoprotein cholesterol (HDL-C), Low-density Lipoprotein 
cholesterol (LDL-C), and LDL-C sub groups (LDL-C I, LDL-C II, LDL-C III, LDL-C IV, LDL-C V) were done 
for all subjects at 2 visits separated by 1 week, and the means were used as baseline values. Non-
High-density Lipoprotein cholesterol (non-HDL-C) was calculated by subtracting HDL-C from TC. 
After baseline measurements, all 44 subjects were randomized by www.randomizer.com in equal 
numbers to receive either EPA (%75) & DHA (%25) 4g/day ethyl esters (Peak EPA, Wiley’s Finest™) 
or olive oil (placebo) 4g/day for 8 weeks in combination with the same dose of atorvastatin they 
have been prescribed to. The total EPA and DHA dose recommended by American Heart 





therapeutic dose used in several major clinical trials including COMBOS, MARINE, ESPIRIT, 
EVOLVE, ANCHOR. For all subjects, atorvastatin dosage has been kept constant throughout the 
trial. 
Both groups took 4 one-g capsules orally 4 times daily and compliance was measured by 
the number of capsules consumed relative to the number estimated to be consumed. OM-3 
tablets included EPA&DHA ethyl esters (1000g), other OM-3 FA (60 mg), fish gelatin, glycerine, 
purified water and alpha tocopherol, while placebo tablets contained extra virgin olive oil 
(1000g0, bovine gelatin, glycerine, purified water.  
Baseline measurements were repeated at the end of week 8. Study participants and 
investigators remained blinded to all laboratory results until the last subject completed the 8-
week intervention period. During the treatment phase, subjects attended clinic visits at weeks 4 
and 8. 
Biochemical Measurements  
Laboratory analyses were performed by Pax Clinic (Istanbul, Turkey) on the serum or 
plasma of 12 hours fasting blood samples. LDL-C, VLDL-C and HDL-C were measured with 
homogeneous enzymatic colorimetric assay of Roche Diagnostics (USA). TAG and TC was 
measured with enzymatic colorimetric assay of Roche Diagnostics (USA). LDL-C subgroups were 
analyzed with electrophoresis by Lipoprint (Quantimetrix, USA).  
TC: Cholesterol esters were cleaved by cholesterol esterase to produce free cholesterol 
and FA. Cholesterol oxidase then catalysed the oxidation of cholesterol to cholest‑4‑ en‑ 3‑ one 





oxidative coupling of phenol and 4‑ aminophenazone to form a red quinone‑ imine dye. The 
colour intensity of the dye formed was proportional to the cholesterol concentration. It was 
determined by measuring the increase in absorbance. 
HDL: In the presence of magnesium ions, dextran sulfate selectively formed 
water‑ soluble complexes with LDL-C, VLDL-C and chylomicrons which were resistant to 
PEG‑modified enzymes. The cholesterol concentration of HDL‑ C was determined enzymatically 
by cholesterol esterase and cholesterol oxidase coupled with PEG to the amino groups. 
Cholesterol esters were broken down quantitatively into free cholesterol and FA by cholesterol 
esterase. In the presence of peroxidase, the hydrogen peroxide generated reacted with 
4‑ amino‑ antipyrine and HSDA to form a purple‑ blue dye. The colour intensity of this dye was 
directly proportional to the cholesterol concentration and was measured photometrically. 
LDL: Cholesterol esters and free cholesterol in LDL were measured on the basis of a 
cholesterol enzymatic method using cholesterol esterase and cholesterol oxidase in the presence 
of surfactants which solubilize only LDL. The enzyme reactions to the lipoproteins other than LDL 
were inhibited by surfactants and a sugar compound. Cholesterol in HDL-C and VLDL-C was not 
determined. Cholesterol esters were broken down quantitatively into free cholesterol and FA by 
cholesterol esterase. In the presence of oxygen, cholesterol was oxidized by cholesterol oxidase 
to Δ4‑ cholestenone and hydrogen peroxide. In the presence of peroxidase, the hydrogen 
peroxide generated reacted with 4‑ aminoantipyrine and EMSE to form a red purple dye. The 






LDL-C sub fractions: Lipophilic dye binded proportionally to the relative amount of 
cholesterol in each lipoprotein and the prestained lipoproteins subsequently underwent 
electrophoresis. During the first phase of electrophoresis, the lipoprotein particles were 
concentrated by the loading and stacking gels into a sharp narrow band. As the lipoprotein 
particles migrated through the separating gel matrix, they were resolved into lipoprotein bands 
according to their particle sizes from largest to smallest due to the sieving action of the gel.  
Statistical Analysis  
Power analysis was performed by using the G*Power software (v3.1.9) program to 
determine the sample size. At the baseline, a pilot study was performed with 10 people in each 
group. When the percentage change in non-HDL values of the groups was investigated, this was 
found to be 3.25±17.02 in the control group and -8.86±3.81 in OM-3 group. According to 
evaluation performed by using these data, effect size was calculated to be d=0.982 and each 
group should include 18 people to obtain 80% power at a level of α=0.05. Sample size was 
assigned as 44 to allow for subject attrition and other potential causes of study withdrawal up to 
20%. Demographic and baseline analysis were performed for all study participants, while efficacy 
analysis were performed only on subjects that successfully completed 8-weeks study protocol. 
The primary efficacy end point was non-HDL and LDL-C III particle concentration percentage 
change from baseline; secondary efficacy end points were changes in TAG, TC, LDL-C, VLDL-C and 
HDL-C.  
Normal distribution of the sample was checked with Shapiro-Wilk's test given the fact that 
sample size is less than 100 (Coakes & Steed, 2013). Independent samples t-test was used for the 





test was used for the intergroup comparisons of quantitative variables without normal 
distribution. Paired Samples t-test was used for the in-group comparisons of quantitative 
variables with normal distribution and Wilcoxon Signed Ranks test was used for the in-group 
comparisons of quantitative variables without normal distribution. Pearson's chi-square test was 
used for comparison of qualitative data. Levene's test was conducted to check homogeneity of 




Of the 44 subjects randomly assigned to the trial, 41 have completed it. In the treatment 
arm, 1 subject reported adverse effect (nausea) and 1 was lost to follow-up, while in the placebo 
group 1 subject was lost to follow-up.  
The baseline demographics of the patients are listed in Table 6. The subjects were 
predominantly men (63%) with a mean age of 60.62±9.56 years and body mass index of 23.8±3.0 
kg/m2. No statistically significant difference was determined between groups regarding age, BMI 
values and gender ratios; as well as baseline TAG, TC, HDL-C, non-HDL-C, LDL-C, VLDL-C, LDL-C I, 
LDL-C II and LDL-C III values (p>0.05) (Table 6 & Table 8). 
Table 6 Baseline Characteristics of the Participants 
 Control (n=21) OM-3 (n=20) 
p 
Mean±SD Mean±SD 





BMI (kg/m2) 24.10±2.94 23.50±3.17 0.525 
Gender, n (%) Female 8 (36.4) 8 (36.4) b0.999 
Male 14 (63.6) 14 (63.6) 
 
Diet 
The analysis of total energy derived from dietary components shows no significant 
difference between the groups (Table 7). 
Table 7 Comparison of diets during the intervention periods as assessed by dietary records 
 
Dietary Compounds Control  OM-3  
p 
Median (Q1, Q3) Median (Q1, Q3) 
Total energy (kcal) 3222 (3090, 3420) 3274 (3105, 3420) 0.879 
Total energy (MJ) 13.5 (12.9, 14.3) 13.7 (13.0, 14.3)  
CHO (%E) 51.25 (50.8, 52) 51.25 (50.9, 52) 0.629 
     Free Sugars (%E) 5.25 (5.1, 6.1) 5.25 (5.2, 5.3) 0.820 
Protein (%E) 16.4 (16.3, 17.2) 16.4 (15.9, 17.1) 0.378 
Fat (%E) 32.1 (31.4, 32.9) 32.1 (30.7, 32.7) 0.859 
    SFA (%E) 9.5 (8.9, 9.9) 9.5 (8.9, 9.8) 0.962 
   MUFA (%E) 10.9 (10.6, 11.3) 11.2 (10.6, 11.9) 0.364 
   PUFA (%E) 9.25 (8.8, 9.6) 9.25 (8.8, 10.8) 0.972 
  EPA (%E) 0.91 (0.89, 0.98) 0.91 (0.89, 0.97) 0.730 
  DHA (%E) 0.92 (0.91, 0.97) 0.92 (0.91, 0.97) 0.392 









Baseline and week 8 values as well as percentage change from baseline to the end of 
treatment for the primary and secondary endpoints are shown in Table 8. 
Table 8 Outcome variables at baseline and the end of treatment in mmol/L and their percent change (%) 
 Control (n=21) OM-3 (n=20) 
p 
Mean±SD Mean±SD 
TAG Baseline 1.61±0.85 1.62±0.60 0.924 
8 week 1.66±0.86 1.29±0.37 0.090 
% Difference 6.20±10.14* -21.51±12.15*** <0.001*** 
TC Baseline 4.97±0.81 4.91±0.72 0.820 
8 week 5.05±0.83  4.55±0.65 0.049* 
% Difference 2.06±2.97** -6.55±3.59*** <0.001*** 
HDL-C Baseline 1.40±0.47 1.34±0.32 0.677 
8 week  1.42±0.49  1.37±0.30 0.716 
% Difference 2.90±6.73* 1.09±6.97 0.403 
Non-HDL-C Baseline 3.55±0.60 3.47±0.59 0.999 
8 week 3.62±0.72 3.20±0.54 0.042* 
% Difference 4.65±21.00 -9.47±4.58*** 0.007** 
LDL-C Baseline 2.61±0.65  2.66±0.61 0.831 
8 week 2.64±0.61  2.64±0.55 0.985 
% Difference 0.91±4.35 -0.08±5.20 0.510 
VLDL-C Baseline 0.93±0.25 0.90±0.29 0.684 
8 week 0.98±0.25 0.55±0.20 <0.001*** 
% Difference 3.95±9.93 -36.88±11.75*** <0.001*** 
LDL-C I Baseline 1.07±0.35 1.03±0.30 0.689 
8 week 1.08±0.36 1.03±0.24 0.647 





 Control (n=21) OM-3 (n=20) 
p 
Mean±SD Mean±SD 
LDL-C II Baseline 0.56±0.20 0.63±0.26 0.381 
8 week 0.56±0.19 0.67±0.30 0.209 
% Difference -0.74±16.24 1.55±17.27 0.664 
LDL-C III,  
median (Q1, Q3) 
Baseline 0.05 (0.02, 0.10) 0.09 (0.05, 0.15) 0.158 
8 week 0.05 (0.02, 0.10) 0.02 (0.00, 0.08) 0.090 
% Difference 0 (0, 0) -67.5 (-100, -31.25)** <0.001*** 
Q1: First quartile Q3: Third quartile          *p<0.05  **p<0.01  ***p<0.001 
 
Primary endpoints 
No statistically significant difference was determined between groups regarding post-
intervention week LDL-C III concentration. The percent change in the control group was not 
found to be significant, however the percent change in OM-3 group at the 8th week from baseline 
was determined to be significant (p< 0.001). Also, the percent change in LDL3 value observed in 
OM-3 group was determined to be significantly different compared to the control group 
(p<0.001). 
8th week non-HDL-C concentration was determined to be significantly lower in OM-3 
group compared to the control group (p= 0.042). No significant change was determined in the 
control group, but the change in OM-3 group at the 8th week from baseline was determined to 
be significant (p<0.001). The percentage change in non-HDL value observed in OM-3 group was 
determined to be statistically significantly different compared to the control group (p= 0.007). 
Secondary endpoints 
The percentage change in TAG concentration of the control group (+6.20±10.14 %) and 





significant (p= 0.012, p<0.001, respectively). However, the percent change observed in OM-3 
group was also determined to be statistically significantly different compared to the control 
group (p<0.001).  
TC at week 8 was determined to be significantly lower in OM-3 group when compared to 
the control group (p= 0.049). The percent change both in the control group (2.06±2.97) and OM-
3 group (-6.55±3.59) at the 8th week from baseline was determined to be significant; respectively 
(p: 0.004), (p<0.001). However, the percentage change observed in OM-3 group was also 
determined to be significantly different compared to the control group (p<0.001).  
No significant difference was determined between groups regarding 8th week HDL-
C concentration. The percent change in the control group at the week 8 from baseline was 
determined to be significant (p=0.049). No significant change was determined in the OM-3 group. 
No significant difference was determined between groups regarding the percentage change 
observed in HDL values. 
Week 8 LDL-C, LDL I and LDL II cholesterol concentrations show no significant difference 
between groups. The percent change of these values in the control and OM-3 groups at the 8th 
week from baseline was not found to be significant. No significant difference was determined 
between groups also regarding the percentage change observed in these values. 
VLDL-C concentration was determined to be significantly lower in OM-3 group compared 
to the control group at week 8 (p<0.001). The percentage change in the control group was not 





significant (p<0.001). The percentage change in VLDL value observed in OM-3 group was 
determined to be significantly different compared to the control group (p<0.001). 
 
*p<0.05  **p<0.01  ***p<0.001 
Figure 2 Mean percent change in TAG, TC, Non-HDL and VLDL from baseline to the end or treatment 
 
Discussion  
In this randomized, parallel-group, double-blind, placebo-controlled trial of men and 
women with hyperlipidemia on statins, 4-g/d EPA+DHA supplementation produced significant 
reductions in the primary endpoints non-HDL-C and LDL-C III particle concentration (-9.47±4.58, 
p<0.001 and  -67.5 (-100, -31.25), p<0.01, respectively) compared with OO.  
The role of marine OM-3 FA in altering LDL-C particle phenotype had not been much 
studied in the past. An early study by Contacos, Barter & Sullivan (1993) reported a significant 






































concentration was not measured in this study. In their study of combined therapy with 1.68 g/day 
EPA&DHA with atorvastatin (n=42), Nordøy, Hansen, Brox & Svensson (2001) reported a 
significant %40 (p<0.05) reduction in LDL-C III particle concentration in the treatment arm. 
However, not only this figure was not significantly different than the change in the control group, 
but also the serum concentration of large and buoyant LDL-C I and LDL-C II were also reduced in 
their study as opposed to this one, in which a non-significant increase in large and buoyant LDL-
C particles were also observed, signalling to a shift within the phenotypes. Maki et al. (2008) 
found a significant increase in LDL-C particle size from 19.9 (19.2, 22.0) nm to 20.4 (19.3, 21.7) 
nm (p= 0.024) in their cross-over study (n=39) when 4/g EPA&DHA is combined with simvastatin. 
Different from Contacos, Barter & Sullivan (1993), Maki et al. (2008) also measured LDL-C III 
particle concentration and reported no significant change between control and intervention 
arms. It is of particular importance that this present study showed a difference in LDL-C III particle 
concentration, given the fact that LDL-C III and IV particle concentration is suggested to be a 
stronger predictor of CVD than LDL-C particle size is (Otvos et al., 2006; Cromwell & Otvos, 2004). 
Previous studies have shown similar results regarding the effect of OM3-FA 
supplementation on non-HDL-C level. Davidson et al. (2007) found in COMBOS trial that dietary 
supplementation with 4g/day EPA&DHA during 40 mg/day simvastatin therapy resulted in a 9.1% 
reduction (p<0.001) in non-HDL-C compared to 2.2 % (p<.001) with corn oil. The same dose of 
OM-3 and statin caused 6.9% reduction (p<0.01) in ESPIRIT trial by Maki et al. (2013), compared 
to 0.9% (p>0.05) with olive oil. Similarly, Nordøy et al. (1998), Durrington et al. (2001) and Chan 
et al. (2016) reported approximately 10% significant reduction in non-HDL-C in their studies of 





the past. Maki et al. (2008), for instance, found 40% reduction (p<0.001) in their study of a similar 
design with 39 subjects, however, the control group also showed a remarkably great and 
significant reduction (34%, p<0.001) in that study. Furthermore, in the ANCHOR trial, Ballantyne 
et al. (2012) also reported 15% reduction (p<0.0001) in non-HDL-C. Reason for this could be the 
use of EPA ethyl esters alone in this study, given that EPA might lead to greater average 
reductions in non-HDL-C than DHA (Jacobson, Glickstein, Rowe & Soni, 2012). However, little is 
known about these fatty acids’ solo effects on individual lipids (Mori & Woodman, 2006) and 
available studies point out that they have complementary roles to each other (Schaefer et al., 
2010), therefore their combined use is more widely preferred, as it was done in this study.  
In the present study, the decrease in non-HDL-C cholesterol in the OM-3 group was 
achieved mainly due to lowering of VLDL concentrations (-36.88±11.75 %, p<0.0001), as well as 
other triglyceride-rich lipoproteins such as chylomicron remnants. The significant reduction in 
VLDL-C concentration is consistent with the previous evidence (Davidson et al., 2007; Maki et al., 
2008; Bays et al., 2010; Ballantyne et al., 2012; Maki et al., 2013). In human physiology, increased 
amount of VLDL-C particles positively correlate with increased TAG levels (Dagnelie, Rietveld, 
Swart, Stijinen & van den Berg, 1994). These findings collectively confirm that marine OM-3 down 
regulate VLDL metabolism through decreasing TAG synthesis and increasing triglyceride 
clearance (Harris et al., 1997). 
The significant 21.51±12.15 % (p<0.001) reduction in TAG in the present study is slightly 
smaller than the findings of some of the previous studies. Kastelein et al. (2014) reported a 31% 
reduction (p<0.001) and Bays et al. (2011) reported 33% (p<0.0001) reduction in serum TAG with 





OM-3 dose is combined with statin.  The relatively smaller reduction in TAG achieved in this study 
might be due to the difference in the baseline characteristics of the subjects when compared to 
the abovementioned studies. Baseline TAG of the intervention group (145.05±52.67 mg/dL, 
1.62±0.60 mmol/l) was much less than EVOLVE and MARINE and trials (655 and 679 mg/dL, 7.40 
and 7.67 mmol/l, median values, respectively) and the percent reduction in TAG levels highly 
depends on the baseline values (Weintraub, 2014; Harris et al., 1997). Supportive of this, the 
baseline TAG value of the OM-3 group in ESPIRIT trial (Maki et al., 2013) was 287± 82.8 mg/dL 
(3.25±0/94 mmol/l) and the achieved reduction in serum TAG was −20%, (p<0.01), similar to this 
study.  
Reducing blood TAG concentration is important for two reasons. First of all, TAG, as the 
substrate of LDL-C synthesis, is deemed as a target in clinical management of dyslipidemia and 
each 1 mmol/l reduction in TAG levels is believed to reduce CV risk by 14% in men and 37% in 
women (Hokanson & Austin, 1996). More importantly, it has been long known that clinically 
significant reductions in TAG levels is typically accompanied by a shift in LDL particle size from 
smaller and denser particles (LDL-C III, IV) to larger and more buoyant particles (LDL-C I, II) (Krauss 
& Dreon, 1995). Serum TAG concentration is inversely related to the LDL-C particle size and it can 
been hypothesized that reducing TAG would result in an increase in LDL-C particle size (Watson 
et al., 1994). In this study, the significant decrease in serum concentration of LDL-C III (-67%, 
p<0.01) from 3.5 mg/dL to 1 mg/dL in the OM-3 group and the increase (albeit not significant) in 
LDL-C I from 39.86±11.69 mg/dL to 40.25±8.96 mg/dL and in LDL-C II from 24.45±10.22 mg/dL to 





In the control group, TC, TAG and HDL-C at week 8 had shown significant changes from 
baseline, although values are minor. One possible explanation why control group changes 
occurred in the present study is that late-onset effects of the dietary run-in and continued 
adherence to the healthy & balanced diet might have improved these variables.  
The present study has certain limitations. First of all, small sample size and short 
intervention duration limits the conclusions that can be drawn. Although the lipid alterations 
achieved in this study are consistent with the findings of larger studies with longer duration, 
findings should still be confirmed in a larger population. Furthermore, the capsule load was high 
(4 capsules per day) and compliance was measured only by capsule count. Ideally, it needs to be 
confirmed by blood tests of EPA and DHA fatty acids. In this study, a supplemental form of OM-
3 containing EPA & DHA in ethyl ester form was used. However, recent studies point out that EPA 
& DHA in free fatty acids (FFA) form may have 4-fold greater bioavailability than OM-3 ethyl 
esters (Davidson et al., 2012) given that their absorption does not involve pancreatic lipase (Maki 
et al., 2013). Particularly when taken on an empty stomach, FFA formulation would have provided 
great flexibility in the dosing schedule. However, this prescription OM-3 is not available in the 
Turkish market. 
The use of OO as a control might had certain non-neutral effects on the outcome variables 
due to its high oleic acid content and the role of oleic acid in CVD prevention (Pineo & Anderson, 
2008). However, 4 g/day is a too low dose to bias the result, especially when compared to the 
amount used in studies such as PREDIMED, which showed that 50 g/day use of OO showed 







There is a clinical need to effectively reduce small&dense LDL-C particle concentration for 
CVD prevention. Agents that lower blood TAG are usually successful in altering LDL-C particle 
phenotype. However, efficacy of OM-3 FA, which is a TAG lowering agent, in LDL-C particle 
altering has been much investigated. In this double-blind, randomized, controlled trial of 
combined use of OM-3 FA with atorvastatin in patients with hyperlipidemia, supplementation of 
EPA and DHA at 4 g/d dosage improved the overall lipid profile in 8 weeks, including significant 
lowering of LDL-C III and non-HDL-C concentrations. Further studies are required to confirm the 
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